Cite
Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma.
MLA
Frigault, Matthew J., et al. “Phase 1 Study of CART-DdBCMA for the Treatment of Subjects with Relapsed and Refractory Multiple Myeloma.” Blood Advances, vol. 7, no. 5, Mar. 2023, pp. 768–77. EBSCOhost, https://doi.org/10.1182/bloodadvances.2022007210.
APA
Frigault, M. J., Bishop, M. R., Rosenblatt, J., O’Donnell, E. K., Raje, N., Cook, D., Yee, A. J., Logan, E., Avigan, D. E., Jakubowiak, A., Shaw, K., Daley, H., Nikiforow, S., Griffin, F., Cornwell, C., Shen, A., Heery, C., & Maus, M. V. (2023). Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma. Blood Advances, 7(5), 768–777. https://doi.org/10.1182/bloodadvances.2022007210
Chicago
Frigault, Matthew J, Michael R Bishop, Jacalyn Rosenblatt, Elizabeth K O’Donnell, Noopur Raje, Daniella Cook, Andrew J Yee, et al. 2023. “Phase 1 Study of CART-DdBCMA for the Treatment of Subjects with Relapsed and Refractory Multiple Myeloma.” Blood Advances 7 (5): 768–77. doi:10.1182/bloodadvances.2022007210.